Abstract
Particulate structures hold great promise for the development of effective and affordable recombinant prophylactic as well as therapeutic vaccines. Different types of particulate structures, including virus-like particles (VLPs) and virosomes, have been developed depending on the nature of the viral pathogen to be targeted and the type of immune response (humoral vs cellular) to be elicited. Particulate structures allow the insertion or fusion of foreign antigenic sequences, resulting in chimeric particles delivering foreign antigens on their surface. Similarly, they are used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation. Particulate structures, indeed, represent a very efficient system for delivering antigens to antigen presenting cells (APC) which, in turn, trigger and amplify the adaptive immune response. The present review will address the biological and immunological properties of particulate structures, in particular VLPs, as platform for vaccine development.
Keywords: Virus-like particles, vaccine, antigen-presenting cells, HIV, innate immunity, adaptive immunity
Current HIV Research
Title: Virus-Like Particles as Particulate Vaccines
Volume: 8 Issue: 4
Author(s): Luigi Buonaguro, Maria L. Tornesello and Franco M. Buonaguro
Affiliation:
Keywords: Virus-like particles, vaccine, antigen-presenting cells, HIV, innate immunity, adaptive immunity
Abstract: Particulate structures hold great promise for the development of effective and affordable recombinant prophylactic as well as therapeutic vaccines. Different types of particulate structures, including virus-like particles (VLPs) and virosomes, have been developed depending on the nature of the viral pathogen to be targeted and the type of immune response (humoral vs cellular) to be elicited. Particulate structures allow the insertion or fusion of foreign antigenic sequences, resulting in chimeric particles delivering foreign antigens on their surface. Similarly, they are used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation. Particulate structures, indeed, represent a very efficient system for delivering antigens to antigen presenting cells (APC) which, in turn, trigger and amplify the adaptive immune response. The present review will address the biological and immunological properties of particulate structures, in particular VLPs, as platform for vaccine development.
Export Options
About this article
Cite this article as:
Buonaguro Luigi, L. Tornesello Maria and M. Buonaguro Franco, Virus-Like Particles as Particulate Vaccines, Current HIV Research 2010; 8 (4) . https://dx.doi.org/10.2174/157016210791208659
DOI https://dx.doi.org/10.2174/157016210791208659 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Supramolecular Nanomedicine - An Overview
Current Drug Targets Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology A Technological Update of Molecular Diagnostics for Infectious Diseases
Infectious Disorders - Drug Targets Beneficial Effect of Peptides from Microalgae on Anticancer
Current Protein & Peptide Science Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine
Recent Patents on Nanomedicine The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets Epothilone B and its Analogs - A New Family of Anticancer Agents
Mini-Reviews in Medicinal Chemistry Cyanidin 3-O-Glucoside Induces the Apoptosis in the Osteosarcoma Cells through Upregulation of the PPARγ and P21: An <i>In Vitro</i> Study
Anti-Cancer Agents in Medicinal Chemistry Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Current Drug Targets Application of Charge Transfer Reactions for the Quantitative Spectrophotometric Determination of Cyclophosphamide in Pure and Pharmaceutical Formulation
Current Pharmaceutical Analysis Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field
Current Gene Therapy The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment
Current Medicinal Chemistry Pharmacoepigenomics: An Interplay of Epigenetic Modulation of Drug Response and Modulation of the Epigenome by Drugs
Current Pharmaceutical Design STAT3: A Potential Drug Target for Tumor and Inflammation
Current Topics in Medicinal Chemistry Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?
CNS & Neurological Disorders - Drug Targets The Therapeutic Potential of Small Activating RNAs for Colorectal Carcinoma
Current Gene Therapy Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Amyotrophic Lateral Sclerosis: A Genetic Point of View
Current Molecular Medicine Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?
Reviews on Recent Clinical Trials Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study
Current HIV Research